ArticleImmunology2006
Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha.
Article in Immunology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 52 citations in OpenAlex.
- Article
- A metabolic perspective on nitric oxide function in melanoma.Biochimica et biophysica acta. Reviews on cancer · 2024Review
- Tumor-associated myeloid cells in cancer immunotherapy.Journal of hematology & oncology · 2023Review
- Manipulation of the tumor immuno-microenvironment via TAM-targeted expression of transcription factors.Immunologic research · 2022Review
- Dynamic CD8Cancers · 2022Review
- Review
- Article
- Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives.Breast cancer (Tokyo, Japan) · 2021Review
- Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad.International journal of molecular sciences · 2020Review
- Tumor-Associated Neutrophils and Macrophages-Heterogenous but Not Chaotic.Frontiers in immunology · 2020Review
- Experimental Combined Immunotherapy of Tumours with Major Histocompatibility Complex Class I Downregulation.International journal of molecular sciences · 2018Article
- CD40-mediated signalling influences trafficking, T-cell receptor expression, and T-cell pathogenesis, in the NOD model of type 1 diabetes.Immunology · 2017Article
- Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies.Frontiers in immunology · 2017Review
- Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.Cancer immunology research · 2016Article
- C57BL/6N Mice Are More Resistant to Ehrlich Ascites Tumors Than C57BL/6J Mice: The Role of Macrophage Nitric Oxide.Medical science monitor basic research · 2015Article
- Macrophages Reprogrammed In Vitro Towards the M1 Phenotype and Activated with LPS Extend Lifespan of Mice with Ehrlich Ascites Carcinoma.Medical science monitor basic research · 2015Article
- Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site.Oncotarget · 2015Article
- Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages.Molecular immunology · 2015Article
- Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.Seminars in oncology · 2015Review
- Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.Cancer immunology, immunotherapy : CII · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Effector cells of the innate immune system have diverse functions that can result in tumour inhibition or tumour progression. Activation of macrophages by CD40 ligation has been shown to induce antitumour effects in vitro and in vivo. Here we investigated the role of nitric oxide (NO) and tumour necrosis factor-alpha (TNF-alpha) as mediators in the tumoristatic effects of murine peritoneal macrophages activated with agonistic anti-CD40 monoclonal antibody (alphaCD40) alone and following further stimulation with bacterial lipopolysaccharide (LPS). We found that macrophages activated in vivo by alphaCD40 exhibited tumoristatic activity in vitro against B16 melanoma cells; the tumoristatic effect correlated with the level of NO production and was enhanced by LPS. Use of the NO inhibitor L-nitro-arginine-methyl esterase (L-NAME) and evaluation of macrophages from inducible NO synthase (iNOS)-knockout (KO) mice following alphaCD40 activation showed reduced tumoristatic activity. CD40 ligation enhanced expression of TNF-alpha. Macrophage tumoristatic activity following alphaCD40 treatment was reduced by TNF-alpha mAb or use of macrophages from TNF-alpha-KO mice. However, further stimulation of alphaCD40-activated macrophages with LPS resulted in strong tumoristatic activity that was much less dependent on NO or TNF-alpha. Taken together, these results suggest that NO and TNF-alpha are involved in, but not solely responsible for, the antitumour effects of macrophages after activation by CD40 ligation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.